Magnetic resonance markers for early diagnosis and progression of Alzheimer's disease.
With increasing life expectancy, the early diagnosis and treatment of Alzheimer's disease has become critical in sustaining a healthy society. Noninvasive markers of disease progression starting from the earliest stages of pathologic involvement are required for determining the effectiveness of putative disease-modifying therapies that are under development. Cross-sectional and longitudinal studies indicate that magnetic resonance-based volume measurements of atrophy are potential markers of the progression of Alzheimer's disease, starting from the preclinical stages. Other magnetic resonance techniques that are sensitive to the different aspects of Alzheimer's disease pathology, such as biochemical ((proton) magnetic resonance spectroscopy), microstructural (diffusion magnetic resonance imaging), functional (functional magnetic resonance imaging) and blood flow (perfusion magnetic resonance imaging) changes, have not been as extensively studied longitudinally. Recent efforts of imaging amyloid plaques with magnetic resonance imaging generate the prospect for in vivo imaging of the pathologic substrate of Alzheimer's disease in the future. In order for magnetic resonance modalities to qualify as surrogate markers for early diagnosis and progression of Alzheimer's disease, multicenter longitudinal studies are needed.
Kantarci
Kejal
K
Department of Radiology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. kantarci.kejal@mayo.edu
D000544:Alzheimer Disease / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D015415:Biomarkers; D003952:Diagnostic Imaging / Q000145:classification / Q000379:methods*; D038524:Diffusion Magnetic Resonance Imaging; D018450:Disease Progression; D005104:Expert Testimony; D006801:Humans; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D013997:Time Factors
D015415:Biomarkers